泰坦医学(TSX:TMD)今天说,它计划在公开募股中浮动多达1亿股股票,该股票可能会为其开发的运动机器人辅助手术平台提供多达1,150万美元。
The Toronto-based company said it will offer at least 46.7 million shares at 11.5¢ (C15.0¢) apiece, for minimum gross proceeds of more than $5.3 million (C$7.0 million). Each unit in the offering consists of a stock share and a 5-year warrant priced at 15.3¢ (C20.0¢)
泰坦说,只要第一笔批达到530万美元的门槛,该产品就可以分阶段结束,并补充说,它预计明天将首次结束。该公司表示,该收益专门用于进一步开发运动系统,营运资金和“其他一般目的”。
泰坦说,布鲁姆·伯顿证券(Bloom Burton Securities)是浮选的唯一发行代理商。
本月初,它shareholders approved a reverse stock split在一股5到30股的股份范围内。
泰坦医学在四月份说与中国分销商Longtai Medical的尖峰会谈在其运动机器人辅助手术平台上,它可以专注于在美国和欧洲赢得监管批准。
Back in October 2015, Titan与Longtai达成了私人安置协议, a subsidiary of Chinese medical device distributor Ningbo Long Hengtai International Trade Co., that could have ended up being worth more than $24 million.
($1= C $1.30927)
提交以下:机器人报告

告诉我们你的想法!